Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis

Background Golgi Phosphoprotein 3 (GOLPH3) has been implicated in the development of colorectal cancer (CRC). Nevertheless, the clinicopathological and prognostic roles of GOLPH3 in CRC remain undefined. We thus did a meta-analysis to assess GOLPH3 association with the clinicopathological characteristics of patients and evaluate the prognostic significance of GOLPH3 in CRC. Methods An electronic search for relevant articles was conducted in the PubMed, Cochrane Library, Web of Science, Medline, Embase, CNKI, and WanFang databases. Two independent reviewers searched all the literature and finished the data extraction and quality assessment. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were used to assess estimates. Stata software (version12.0) was employed to analyze the data. Results A total of 8 published studies were eligible (N = 723 participants). Meta-analysis revealed that GOLPH3 was found to be highly expressed in tumor tissues compared to that of adjacent colorectal tissues (OR, 2.63), and overexpression of GOLPH3 had significant relationship with advanced clinical stage (OR, 3.42). GOLPH3 expression was not correlated with gender (OR, 0.89), age (OR, 0.95), positive lymphatic metastasis (OR, 1.27), tumor size (OR, 1.12), poor differentiation of tumor (OR, 0.56) or T stage (OR, 0.70). Moreover, GOLPH3 overexpression was not associated with worse overall survival (OS) (HR = 1.14, 95% CI: 0.42–1.86, P>0.05) and disease-free survival (DFS) (HR = 0.80, 95% CI:-0.26–1.86, P>0.05). Conclusions GOLPH3 overexpression is correlated with tumor stage, which is an adverse clinicopathological characteristic of CRC. But, GOLPH3 can not serve as a useful biomarker in evaluating the progression of CRC.

Download Full-text

Prognostic value of lncRNA ROR expression in various cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20181095 ◽

2018 ◽

Vol 38 (5) ◽

Cited By ~ 5

Author(s):

Renfu Lu ◽

Junjian Chen ◽

Lingwen Kong ◽

Hao Zhu

Keyword(s):

Prognostic Value ◽

Meta Analysis ◽

Clinical Stage ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Advanced Clinical Stage ◽

Non Coding Rna ◽

Meta Analyses

Background: There is a dispute on the prognostic value of long non-coding RNA regulator of reprogramming (lncRNA ROR) in cancers. The purpose of the present study was to evaluate the prognostic significance of lncRNA ROR expression in human cancers. Methods: PubMed, Embase, and Cochrane Library were searched to look for relevant studies. The meta-analyses of prognostic and clinicopathological parameters (CPs) were conducted. Results: A total of ten studies were finally included into the meta-analysis. High lncRNA ROR expression was significantly associated with shorter overall survival (hazard ratio [HR] = 2.88, 95% confidence interval [CI] = 2.16–3.84, P<0.01) and disease-free survival (HR = 3.25, 95% CI = 2.30–4.60, P<0.01) compared with low lncRNA ROR expression. Besides, high lncRNA ROR expression was obviously related to more advanced clinical stage (P<0.01), earlier tumor metastasis (P=0.02), lymph node metastasis (P<0.01), and vascular invasion (P<0.01) compared with low lncRNA ROR expression. However, there was no significant correlation between lncRNA ROR expression and other CPs, including age (P=0.18), gender (P=0.33), tumor size (P=0.25), or tumor differentiation (P=0.13). Conclusion: High lncRNA ROR expression was associated with worse prognosis in cancers. LncRNA ROR expression could serve as an unfavorable prognostic factor in various cancers.

Download Full-text

Claudin-1 Is a Valuable Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis

Gastroenterology Research and Practice ◽

10.1155/2020/4258035 ◽

2020 ◽

Vol 2020 ◽

pp. 1-10

Author(s):

Didi Zuo ◽

Jiantao Zhang ◽

Tao Liu ◽

Chao Li ◽

Guang Ning

Keyword(s):

Colorectal Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Venous Invasion ◽

Lymphatic Invasion ◽

Cochrane Library ◽

Test Sequence ◽

Tumor Type ◽

The Stability

Background. Claudin-1 plays an important part in maintaining the mucosal structures and physiological functions. Several studies showed a relationship between claudin-1 and colorectal cancer (CRC), but its prognostic significance is inconsistent. This meta-analysis assessed the prognostic value and clinical significance of claudin-1 in CRC. Materials and Methods. We retrieved eligible studies from PubMed, Cochrane Library, Embase, and Web of Science databases before February 10, 2020. The hazard ratio (HR) with 95% confidence interval (CI) was applied to assess the correlation between claudin-1 and prognosis and clinical features. Heterogeneity was assessed by the Cochran Q test and I-square (I2), while publication bias was evaluated by the Begg test and Egger test. Test sequence analysis (TSA) was used to estimate whether the included studies’ number is sufficient. The stability of the results was judged by sensitivity analysis. Metaregression was utilized to explore the possible covariance which may impact on heterogeneity among studies. Results. Eight studies incorporating 1704 patients met the inclusion criteria. Meta-analysis showed that the high expression of claudin-1 was associated with better overall survival (HR, 0.46; 95% CI, 0.28–0.76; P=0.002) and disease-free survival (HR, 0.44; 95% CI, 0.29–0.65; P=0.003) in CRC. In addition, we found that claudin-1 was related to the better tumor type (n=6; RR, 0.60; 95% CI, 0.49–0.73; P<0.00001), negative venous invasion (n=4; RR, 0.81; 95% CI, 0.70–0.95; P=0.001), and negative lymphatic invasion (n=4; RR, 0.83; 95% CI, 0.74–0.92; P=0.0009). Conclusion. The increased claudin-1 expression in CRC is associated with better prognosis. In addition, claudin-1 was related to the better tumor type and the less venous invasion and lymphatic invasion.

Download Full-text

Prognostic significance of long non-coding RNA DANCR expression in human cancers: A systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20181627 ◽

2019 ◽

Cited By ~ 1

Author(s):

Wei Liu ◽

Qin-Peng Wang ◽

Jia Guo

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cancer Prognosis ◽

Advanced Clinical Stage ◽

Protein Coding ◽

Human Cancers ◽

Non Coding Rna ◽

Long Non Coding Rna

Background: Several studies demonstrated that long non-coding RNA differentiation antagonizing non-protein coding RNA (lncRNA DANCR) expression might have the potential capacity to predict the cancer prognosis, however, definite conclusion has not been obtained. The aim of this meta-analysis was to evaluate the prognostic value of lncRNA DANCR expression in cancers. Methods: PubMed, Web of Science, Scopus and Embase were comprehensively searched for relevant studies. Studies meeting all inclusion standards were included into this meta-analysis. The analysis of overall survival (OS), disease-free survival (DFS) or clinicopathological features was conducted. Results: Eleven studies containing 1,154 cancer patients were analyzed in this meta-analysis. The results showed, compared with low lncRNA DANCR expression, high lncRNA DANCR expression was significantly associated with shorter OS (HR=1.85, 95%CI=1.52-2.26, P<0.01) and DFS (HR=1.82, 95%=1.43-2.32, P<0.01) in cancers. Besides, high lncRNA DANCR expression predicted deeper tumor invasion (P<0.01), earlier lymph node metastasis (P<0.01), earlier distant metastasis (P<0.01) and more advanced clinical stage (P<0.01) compared with low lncRNA DANCR expression in cancer populations. Conclusion: High lncRNA DANCR expression was associated with worse prognosis compared with low lncRNA DANCR expression in cancers. LncRNA DANCR expression could serve as a prognostic factor of human cancers.

Download Full-text

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis

International Journal of Colorectal Disease ◽

10.1007/s00384-020-03734-4 ◽

2020 ◽

Vol 36 (1) ◽

pp. 117-130

Author(s):

Shuxia Wang ◽

Bo Yuan ◽

Yun Wang ◽

Mingyang Li ◽

Xibo Liu ◽

...

Keyword(s):

Colorectal Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

Clinicopathological Features ◽

Cochrane Library ◽

Free Survival ◽

Meta Regression ◽

Disease Free

Abstract Purpose To systematically evaluate the correlation between PD-L1 expression and clinicopathological features and prognosis of colorectal cancer (CRC). Methods Seven databases (PubMed, Cochrane Library, EMBASE, Web of Science, CBM, Wanfang, and CNKI) were searched through May 2020. Risk of bias and quality of evidence were assessed by using the Newcastle–Ottawa scale (NOS), and meta-analysis was carried out by using the Review Manager 5.3 software on the studies with the quality evaluation scores ≥ 6. Meta-regression analysis was used to determine the independent role of PD-L1 expression on CRC prognosis after adjusting clinicopathological features and treatment methods. Results A total of 8823 CRC patients in 32 eligible studies. PD-L1 expression was correlated with lymphatic metastasis (yes/no; OR = 1.24, 95% CI (1.11, 1.38)), diameter of tumor (≥ 5 cm/< 5 cm; OR = 1.34, 95% CI (1.06, 1.70)), differentiation (high–middle/low; OR = 0.68, 95% CI (0.53, 0.87)), and vascular invasion (yes/no; OR = 0.80, 95% CI (0.69, 0.92)). PD-L1 expression shortened the overall survival (hazard ratio (HR) = 1.93, 95% CI (1.66, 2.25)), disease-free survival (HR = 1.76, 95% CI (1.50, 2.07)), and progression-free survival (HR = 1.93, 95% CI (1.55, 2.41)). Meta-regression showed that PD-L1 expression played a significant role on poor CRC OS (HR = 1.95, 95% CI (1.92, 3.98)) and disease-free survival (HR = 2.14, 95% CI (0.73, 4.52)). Conclusion PD-L1 expression independently predicted a poor prognosis of CRC.

Download Full-text

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20203995 ◽

2021 ◽

Author(s):

Weiwei Chen ◽

Yuting Li ◽

Liliangzi Guo ◽

Chenxing Zhang ◽

Shaohui Tang

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Predictive Marker ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Hazard Ratios ◽

Non Coding Rna ◽

The Relationship ◽

Long Non Coding Rna

Background: Several studies have assessed the relationship between long non-coding RNA five prime to Xist (FTX) expression, clinicopathological features, and survival outcomes in cancer patients with conflicting results. This meta-analysis synthesized existing data to clarify the association between FTX with cancer prognosis.Methods: PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Eleven studies comprising 1,210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma were enrolled in this analysis. The meta-analysis showed that high FTX expression was significantly associated with several clinicopathological characteristics, including lymph node metastasis in patients with CRC, GC, HCC, and RCC, distant metastasis in patients with CRC, GC, HCC, and OSC, larger tumor size in patients with CRC, GC, HCC, RCC, and OSC, and subsequently TNM/clinical stage in patients with CRC, GC, HCC, OSC, and glioma. The pooled results from the survival analysis revealed a significant correlation between high FTX expression and shorter OS in patients with HCC, CRC, GC, OSC, and glioma. Further, FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions: FTX may be a potential oncogene, with high FTX expression being associated with a poorer prognosis in patients with CRC, HCC, OSC, and glioma

Download Full-text

Prognostic significance of LINC00460 overexpression in solid tumours: a meta-analysis

Postgraduate Medical Journal ◽

10.1136/postgradmedj-2019-137172 ◽

2020 ◽

Vol 96 (1135) ◽

pp. 286-295

Author(s):

Chen Dai ◽

Yan Zhang ◽

Hao Ni ◽

Yuting Kuang ◽

Zhihua Xu

Keyword(s):

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Malignant Tumour ◽

Positive Lymph Node ◽

Cochrane Library ◽

Cancer Type ◽

Malignant Tumours ◽

Node Metastasis ◽

Solid Malignant Tumour

The prognostic value of long intergenic non-protein coding RNA 460 (LINC00460) overexpression in human solid malignant tumours remains unclear. Therefore, we conducted the meta-analysis to systematically review and assess the evidence for the correlation between LINC00460 overexpression and clinicopathological features and overall survival (OS) of patients with solid malignant tumour. An electronic search of PubMed, EMBASE, Web of Science, CNKI, Cochrane Library, Chinese Biological Medical Literature database and WanFang database was applied to select eligible articles. Pooled ORs or HRs with their 95% CIs were calculated to estimate the effects. 9 eligible studies with a total of 935 patients were enrolled in this meta-analysis. The results revealed that high LINC00460 expression was associated with positive lymph node metastasis (positive vs negative: OR=2.97, 95% CI 1.74 to 5.05, p=0.812), advanced tumour-node-metastasis stage (III+IV vs I+II: OR=2.82, 95% CI 1.64 to 4.85, p=0.193) and poorer differentiation (high vs low: OR=0.60, 95% CI 0.36 to 0.99, p=0.569). Additionally, the overexpression of LINC00460 could predict a poorer OS (HR=1.57, 95% CI 1.39 to 1.77) and the shorter disease-free survival (HR=2.32, 95% CI 1.25 to 4.31). Furthermore, according to subgroup analysis and meta-regression results, the heterogeneity of current meta-analysis may be attributed to the differences of cancer type and follow-up months. High expression of LINC00460 could predict poor prognosis in patients with solid malignant tumour. LINC00460 may serve as potential prognostic biomarker for clinical outcomes in various human solid malignant tumours.

Download Full-text

Expression of tripartite motif‑containing 44 and its prognostic and clinicopathological value in human malignancies：a meta-analysis

10.21203/rs.3.rs-15897/v2 ◽

2020 ◽

Author(s):

Guoliang Xiao ◽

Qiuxi Yang ◽

Ziwei Bao ◽

Haixia Mao ◽

Yi Zhang ◽

...

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Disease Free Survival ◽

Advanced Clinical Stage ◽

Over Expression ◽

Interactive Analysis ◽

Tumor Tissues ◽

Tripartite Motif ◽

Predictive Role

Abstract Background: Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and to describe its possible mechanisms of oncogenesis. Methods: The available databases worldwide were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies.The hazard ratio (HR) and combined odds ratios (ORs) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software. Results: A total of 1,740 patients from thirteen original studies were finally included in this study . The results of the combined analysis showed that over-expression of TRIM44 was significantly correlated with shorter overall survival (OS) in cancer patients (HR = 2.16, 95% CI: 1.65–2.83) as well as worse disease-free survival (DFS) (HR= 2.13 (95% CI 1.45–3.11). Additionally, the combined ORs indicated that elevated TRIM44 expression was significantly associated with lymph node metastasis (OR=2.69, 95% CI: 1.71–4.24), distant metastasis (OR=10.35, 95% CI: 1.01-106.24), poor tumor differentiation (OR=1.78, 95% CI: 1.03–3.09), increased depth of tumor invasion (OR=2.72, 95% CI: 1.73–4.30), advanced clinical stage (OR=2.75, 95% CI: 2.04-3.71), and recurrence (OR=2.30, 95% CI: 1.34–3.95). Analysis of expression using Gene Expression Profiling Interactive Analysis (GEPIA) indicated that the expression of TRIM44 was higher in most tumor tissues than in the corresponding normal tissues.Survival analysis indicated high levels of TRIM44 mRNA were associated with unfavorable OS and DFS in various malignancies. Conclusions: TRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.

Download Full-text

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

10.21203/rs.3.rs-20428/v3 ◽

2020 ◽

Author(s):

Yiding Li ◽

Guiling Wu ◽

Wanli Yang ◽

Xiaoqian Wang ◽

Lili Duan ◽

...

Keyword(s):

Therapeutic Response ◽

Meta Analysis ◽

Prognostic Significance ◽

Pooled Analysis ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Cellsearch System ◽

Poor Overall Survival ◽

Response To Chemotherapy ◽

The Cochrane Library

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumor in the world, which is still one of the primary causes of tumor-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding effective treatment. Recently, circulating tumor cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined by the CellSearch system in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect values. Results: Totally 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher rate of CTCs compared with the I/II group (OR=1.36, 95% CI: 0.68-2.71, I2=0%). Incidence of CTCs was higher in patients with T3/T4 stage (OR=2.92, 95% CI: 1.31-6.51, I2=0%) and distant metastasis group (OR=5.18, 95% CI: 2.38-11.25, I2=0%) compared to patients with T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR=2.83, 95% CI:1.99-4.03, I2=0%) and relapse-free survival (RFS) (HR=4.71, 95% CI:2.73-8.13, I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR=1.99, 95% CI:1.73-2.29, I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs positivity determined by the CellSearch system are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

Download Full-text

The Prognostic Roles and Clinical Features of CD44v9 in Human Solid Cancers—A Meta-Analysis

10.21203/rs.3.rs-54020/v1 ◽

2020 ◽

Author(s):

Yuanxiu Deng ◽

Jie Wang ◽

Shenhui Ji ◽

Lu Huang ◽

Meijiang Feng

Keyword(s):

Clinical Features ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

High Expression ◽

Cochrane Library ◽

Cancer Specific Survival ◽

Free Survival ◽

Diagnosis And Prognosis

Abstract Background: CD44 is the primary receptor for hyaluronic acid and serves as a marker for cancer stem cells. CD44v9 is one of CD44’s variants and takes part in cancer’s growth and metastasis. However, the prognostic roles and clinical features of CD44v9 in cancers remain unclear. Therefore, we conducted this meta-analysis to summarize the prognostic significance and clinical features of CD44v9 in human solid cancers.Methods: we systematically searched all of related studies in PubMed, the Web of Science, Embase and Cochrane library up to June 2020. We analyzed the pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) to assess the prognostic functions and clinical features of CD44v9 in various human solid cancers.Results: In this meta-analysis, we included 1705 cancer patients among 12 studies. Results indicated that high expression of CD44v9 was significantly related to poorer overall survival (OS) (HR=1.60, 95%CI 1.28-1.99, P<0.0001), recurrence-free survival/progression-free survival/disease-free survival (RFS/PFS/DFS).( HR=1.81, 95%CI 1.16-2.84, P=0.009) and disease-specific survival/cancer-specific survival (DSS/CSS) (HR=2.93, 95%CI 1.69-5.10, P<0.001). At the same time, we also found that high expression of CD44v9 increased the possibility of lymphoid infiltrates (OR=1.59, 95%CI 1.16-2.20, P=0.005), vascular invasion (OR=1.57, 95%CI 1.11-2.22, P=0.010) and higher TNM stage (OR=1.63, 95%CI 1.19-2.23, P=0.002).Conclusion: Our results demonstrate that CD44v9 overexpression is associated with worse OS, RFS/PFS/CFS and DSS/CSS in patients with solid cancers, which might be a biomarker in the diagnosis and prognosis of cancers in the future.

Download Full-text

Diagnostic and prognostic significance of dysregulated expression of circular RNAs in osteosarcoma

10.21203/rs.3.rs-19087/v1 ◽

2020 ◽

Author(s):

Chenghao Zhang ◽

Jieyu He ◽

Lin Qi ◽

Zhixi Duan ◽

Lu Wan ◽

...

Keyword(s):

Meta Analysis ◽

Prognostic Significance ◽

Area Under The Curve ◽

Disease Free Survival ◽

Diagnostic Odds Ratio ◽

Cochrane Library ◽

Clinicopathological Parameters ◽

Circular Rnas ◽

Diagnostic Significance ◽

Enneking Stage

Abstract Background Circular RNAs (circRNAs) have emerged as pivotal regulators in osteosarcoma tumorigenesis and progression, but their prognostic and diagnostic significance remain unclear. Herein, we aimed to perform an updated meta-analysis to explore the clinical, diagnostic and prognostic values of circRNAs in osteosarcoma. Methods Several databases, including PubMed, Web of Science, EMBASE, Scopus and Cochrane Library, were systematically searched up to Mar 10, 2020. Eligible studies regarding the relationship between circRNAs levels and clinicopathological, diagnostic and prognostic values in osteosarcoma patients were included in this study. Pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to measure clinical characteristics, while hazard ratios (HRs) with 95% CIs were adopted to assess overall survival (OS) and disease-free survival (DFS). Results Overall, 26 relevant studies involving 1,652 patients with osteosarcoma were enrolled, with eighteen studies on clinicopathological parameters, ten on diagnosis and eighteen on prognosis. For clinical parameters, overexpression of oncogenic circRNAs was intimately correlated with larger tumor size (P <0.00001), advanced Enneking stage (P <0.00001), poor differentiation (P =0.0001), and distant metastasis (DM) (P <0.00001). In contrast, the downregulated circRNAs showed negative correlation with Enneking stage (P=0.002) and DM (P<0.0001). For the diagnostic values, the summary area under the curve (AUC) of circRNA for the discriminative efficacy between osteosarcoma patients and non-cancer counterparts was estimated to be 0.86 (95% CI: 0.83-0.89), with a weighted sensitivity of 0.80 (95% CI: 0.74-0.84), specificity of 0.80 (95%: 0.75-0.84), and diagnostic odds ratio (DOR) of 15.48 (10.85-22.10), respectively. For the prognostic significance, oncogenic circRNAs had poor OS (HR=1.92, 95% CI: 1.68-2.19) and DFS (HR=2.65, 95% CI: 2.02-3.49), while elevated expression of tumor-suppressor circRNAs were closely related to longer OS (HR=0.44, 95% CI: 0.28-0.69). Conclusions Taken together, our study showed that aberrantly expressed circRNA signatures could serve as potential predictive indicators in diagnosis and prognosis in patients with osteosarcoma.

Download Full-text